AZD0292

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Pseudomonas Aeruginosa

#DrugCompanyPhaseTrials

1

AZD0292

AstraZeneca

Phase 2

22

Pseudomonas Aeruginosa

QQilu Hospital of Shandong University

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pseudomonas Aeruginosa2 trials

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Recruiting·AstraZeneca·Phase 2·NCT07088926·435 enrolled

A Phase II Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Recruiting·AstraZeneca·Phase 2·NCT07774403·84 enrolled

Single Ascending Dose1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06311760·32 enrolled

Unspecified1 trial

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Japanese Participants

Completed·AstraZeneca·Phase 1·NCT07222254·18 enrolled

Details

Drug Info

Related News